Here are some interesting news from RSNA. I hope we see some good news from Caprius.
//
Advanced Magnetics' Products Receive Positive Review at RSNA '97; Feridex I.V. Shows Benefits in Comparison to Contrast
Enchanced CT
CAMBRIDGE, Mass., and CHICAGO, Dec. 3 /PRNewswire/ -- Advanced Magnetics, Inc. (Amex: AVM) today announced that at the Radiological Society of North America (RSNA) conference, currently underway, the Company's magnetic resonance imaging (MRI) contrast agents, Combidex(R), Feridex I.V.(R) and GastroMARK(R), are featured in several scientific sessions over the course of the five-day industry conference. The benefits of contrast enhanced MRI, including comparisons to contrast enhanced CT, are a popular area of
discussion at RSNA.
"The number of scientific sessions on our products reflects the Company's cutting edge technology and the importance we believe these products have in the future of diagnostic imaging," stated Jerome Goldstein, Chairman and CEO of Advanced Magnetics. "Not only are we seeing positive feedback on Feridex I.V. in the clinic, but we are also seeing the presentation of encouraging data on studies involving Combidex in lymph node imaging." Combidex is currently in Phase III clinical trials for the detection and staging of metastatic disease in lymph nodes. Advanced Magnetics has already completed Phase III clinical trials of Combidex for the diagnosis and characterization
of liver lesions. The Company anticipates filing a New Drug Application (NDA) for both indications in late 1998 or early 1999.
Feridex I.V., the Company's contrast agent for the detection of liver
lesions, is the first in the class of organ-specific MRI contrast agents to be marketed worldwide. GastroMARK oral contrast agent, for use in conjunction with MRI to distinguish the loops of the bowel from other abdominal structures, is the only oral MRI contrast agent currently being marketed in the United States. Advanced Magnetics, Inc. is a pharmaceutical company involved in the development and manufacture of MRI contrast agents for the diagnosis of cancer
and other diseases as well as the development of targeted therapeutics for the treatment of liver diseases and other organ-specific diseases.
Any statements which are not historical facts contained in this press
release are forward-looking statements that involve risks and uncertainties, including but not limited to those relating to the development and commercialization of the Company's products. Please refer to other risks identified in Advanced Magnetics, Inc.'s Securities and Exchange Commission filings.
SOURCE Advanced Magnetics, Inc.
CONTACT: Jerome Goldstein, Chairman and CEO of Advanced
Magnetics, Inc., 617-354-3929
//
Regards Joerg
(still believing against the whole in my portofolio) |
